Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens.
Liu X, Jia S, Chu Y, Tian B, Gao Y, Zhang C, Zheng Y, Jia W, Liu X, Yuan R, Zhang N, Feng J, Dong H, Xin X, Chang Z, Cao Z, Tang H, Gao G.
Liu X, et al.
Front Oncol. 2022 Sep 14;12:938550. doi: 10.3389/fonc.2022.938550. eCollection 2022.
Front Oncol. 2022.
PMID: 36185185
Free PMC article.